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Abstract. The hyaluronan (HA)-binding function (lec- 
tin function) of the leukocyte homing receptor, CD44, 
is tightly regulated. Herein we address possible mecha- 
nisms that regulate CD44 isoform-specific HA binding. 
Binding studies with melanoma transfectants express- 
ing CD44H, CD44E, or with soluble immunoglobulin 
fusions of CD44H and CD44E (CD44H-Rg, CD44E- 
Rg) showed that although both CD44 isoforms can 
bind HA, CD44H binds HA more efficiently than 
CD44E. Using CD44-Rg fusion proteins we show that 
the variably spliced exons in CD44E, V8-V10, specifi- 
cally reduce the lectin function of CD44, while replace- 
ment of V8-V10 by an ICAM-1 immunoglobulin do- 
main restores binding to a level comparable to that of 
CD44H. Conversely, CD44 bound HA very weakly 
when exons V8-V10 were replaced with a CD34 mucin 
domain, which is heavily modified by O-linked glycans. 
Production of CD44E-Rg or incubation of CD44E- 
expressing transfectants in the presence of an O-linked 
glycosylation inhibitor restored HA binding to CD44H- 
Rg and to cell surface CD44H levels, respectively. We 
conclude that differential splicing provides a regulatory 
mechanism for CD44 lectin function and that this effect 
is due in part to O-linked carbohydrate moieties which 
are added to the Ser/Thr rich regions encoded by the 
variably spliced CD44 exons. Alternative splicing re- 
suiting in changes in protein glycosylation provide a 
novel mechanism for the regulation of lectin activity. 
C 
D44 represents a heterogeneous group of cell sur- 
face and secreted proteins generated by alternate 
splicing of a single gene (47).  All CD44 isoforms 
contain at the amino terminus an HA-binding domain which 
is composed of two clusters of positively charged amino 
acids (44, 55). Protein heterogeneity arises predominantly 
from the variable splicing of exons encoding extracellular 
domains located between the invariant hyaluronan(HA)  1- 
binding domains and exons encoding the membrane proxi- 
mal extracellular domain (13,23, 33). Alternative splicing 
of exons encoding the cytoplasmic domain of CD44 has 
also been reported (15, 47). To date at least 18 different al- 
ternatively spliced  CD44  isoforms  have  been  reported. 
Cells can express more than one CD44 isoform at a time, 
however, in some cell types one CD44 isoform is preferen- 
tially expressed. Leukocytes predominantly express CD44H 
(50),  an isoform whose extracellular domain contains no 
variably spliced extracellular domain exons, while epithe- 
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1. Abbreviation used in this paper. HA, hyaluronan; MC, melanoma cells; 
RT-PCR, reverse transcriptase-polymerase chain reaction. 
lial cells express many alternatively spliced isoforms (8, 17, 
30, 51). The CD44 isoforms expressed by a given cell can 
also change in response  to differentiation and/or activa- 
tion (1, 28) suggesting that the contribution of CD44 to the 
function of a given cell is not always constant. 
These observations suggest that these  different CD44 
molecules are endowed with distinct and possibly multiple 
functions. Indeed, in  vitro  evidence  supporting  this  hy- 
pothesis has been reported. CD44 is the cell surface recep- 
tor for HA and there is evidence that the binding capaci- 
ties  of  the  various  isoforms  differ  (22,  27,  44,  51).  In 
addition, it has been shown that the CD44 isoforms whose 
extracellular  domain contains variably spliced  exon V3 
can be modified with heparan sulfate and bind to a subset 
of heparin-binding growth  factors  (6,  22).  Other  CD44 
functions have not been so clearly assigned to particular 
isoforms, nonetheless, CD44 is a widely distributed multi- 
functional glycoprotein. Among its many physiological func- 
tions, CD44 has been implicated in leukocyte homing (25), 
leukocyte activation (20, 43, 46), extracellular matrix bind- 
ing (2, 9, 24, 54), and cell adhesion and migration (49, 53). 
Recent experiments have shown that abnormal expression 
of CD44 by tumor cells can enhance their ability to grow 
and/or metastasize in vivo suggesting that abnormal expres- 
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some human cancers (5, 17, 51). 
A  number of different experimental  results lead to the 
conclusion that CD44 functions as a lectin by binding HA. 
These  include  the demonstration that the binding  of HA 
to  cells  expressing  CD44  can  be  blocked  by  anti-CD44 
mAbs (32, 35, 41), the finding that a soluble immunoglob- 
ulin fusion of CD44H  can bind HA  in  a  cell-free  system 
(44),  and the demonstration that a protein recognized by 
mAb K3 which binds to the hamster HA-receptor (52)  is 
the hamster homologue of CD44H (2). These results were 
further supported  by  observations  that  anti-CD44  mAbs 
could  precipitate  [3H]HA-binding  activity  from  murine 
and human cell lines, block the binding of labeled-HA  to 
the receptor and inhibit the HA-dependent aggregation of 
CD44-expressing cells (9, 16). 
In some cell lines  the  lectin  function of CD44  is regu- 
lated (32, 40).  Lesley et al.  (32)  showed that a  number of 
cell  lines  which expressed  high levels  of CD44  bind  HA 
only after activation with phorbol esters. This observation 
has been confirmed using additional cell lines (21, 31), pe- 
ripheral blood lymphocytes (14), and transfected cell lines 
(35, 38), clearly establishing that in some cell types CD44 
lectin function is tightly regulated. Additional studies indi- 
cate that high affinity binding of CD44 for soluble HA re- 
quires an intact cytoplasmic domain (35, 38), CD44 aggre- 
gation on the cell surface (34), protein synthesis (42), and 
cytoplasmic  domain  phosphorylation  (45).  Also,  there  is 
evidence that different CD44 isoforms have different HA- 
binding capacities suggesting that alternative splicing plays 
a  role  in  the  regulation  of the  lectin  function  of  CD44 
(22, 51). 
Here  we report on the results of experiments  designed 
to examine the role of alternative splicing in the regulation 
of  CD44  lectin  function.  Using  CD44-negative  cell  lines 
which were transfected to express either CD44H or CD44E, 
an isoform with  an  extracellular  domain containing vari- 
ably spliced exons V8-V10,  we found that cells expressing 
CD44H bound HA more effectively than cells expressing 
CD44E.  This difference was also seen with soluble immu- 
noglobulin fusion of these two CD44 isoforms. Using solu- 
ble  forms of CD44  which contain peptide  sequences  en- 
coded by one or more of the variably spliced exons found 
in CD44E  or with a  polypeptide  fragment obtained from 
ICAM-1,  we  show  that  inclusion  of  the  CD44  variably 
spliced exons specifically reduces the ability of CD44E  to 
bind  HA.  We  also  present  the  results  of  experiments 
which  suggest  that  the  reduced  HA-binding  capacity  of 
CD44E is due in part to the presence of O-linked carbohy- 
drates which were added to the Ser/Thr rich regions found 
in the variably spliced exons of CD44E (38, 44, 51). 
Materials and Methods 
Cell Culture and Fusion Protein Expression 
CD44  stable  transfected  human melanoma cell  lines,  melanoma cells 
(MC),  have  been  previously  described  (53).  MC44H,  MC44E,  and 
MC44E-trunc express wild-type CD44H, wild-type CD44E, and a CD44E 
deletion mutant which is missing exon E15 and E16 (the junction between 
V10 and E17  is  NVNRSWLI),  respectively. COS  cells were  purchased 
from Amer. Type Culture Collection (Rockville, MD), grown in DMEM/ 
10%  FBS, and used for transient expression of fusion proteins as previ- 
ously described (2). To generate O-linked deglycosylated CD44E-Rg, and 
CD44H-Rg, 1 mM phenyl-c~-N-acetylgalactosaminide  (phenyl-c~-GalNAc) 
(Sigma Immunochemicals, St.  Louis, MO) was added to DMEM during 
the protein production phase of the transfection, and to the melanoma 
transfectants for 16 h before testing HA binding. 
FA  CS Analysis 
The MC transfected cell lines were washed with PBS and added to stain- 
ing media (RPMI/2%  FBS/0.1%  azide). The anti-CD44 mAb A3D8 and 
the  IgGl isotype-matched control  (Sigma  Immunochemicals, St.  Louis 
MO) were added at 10 i~g/ml, and the cells were incubated at 4°C for 30 
min. Excess antibody was washed away with RPMI and an FITC-labeled 
secondary antibody (Tago, Carmarillo, CA) was added for 30 min at 4°C 
followed by washing the cells two more times. The cells were fixed in 
2%  formaldehyde/PBS and analyzed on a FACScan (Becton-Dickinson, 
Mountainview, CA). 
Reverse Transcriptase-PCR 
Total  mRNA was  obtained  from  MC,  MC44H,  MC44E,  and  MC44E- 
trunc  by  guanidine  isothiocyanate/phenol  extraction  as  previously  de- 
scribed (6).  A  random primer method was used to prepare the cDNA for 
PCR.  10 Ixg of total mRNA was incubated with 1 ILl of 0.1 M  Hexamer 
(GIBCO BRL, Gaithersburg, MD) for 10 min at 65°C. Then 4  ILl of 5:,< 
first strand buffer (GIBCO  BRL),  0.1  M  DDT (GIBCO  BRL), 2.5  M 
dNTP's (Boehringer Mannheim Corp., Indianapolis, IN), and 1 I~1 super- 
script RT (GIBCO BRL) was added and incubated for 1 h at 37°C. 30 ~1 
of dH20 was added, and then 3  ixl of the reaction volume was used for 
each PCR reaction. The PCR reactions were carried out in a total volume 
of 50 ~1 with the following reagents added together: (a) 3 ILl of cDNA; (b) 
3 Ixl 1.25 mM dNTP's (Boehringer Mannheim Corp., Indianapolis, IN); (c) 
2.5 ILl each oligonucleotide (10 mM); (d) 5 /~1 10× buffer, and 0.5 U  Taq 
DNA polymerase (Boehringer Mannheim Corp.).  The oligonucleotides 
used as PCR primers included: (a) CD44-E3-FP, GGGGTGTACATCCTC- 
ACATC; (b) CD44-E13-FP, GAAGGCTTGGAAGAAGAT; (c) CD44- 
E17-RP CAAAGCCAAGGCCAAGAGG. The PCR reaction conditions 
were as follows: 94°C for 5 min; 35 cycles were carried out at 94°C for 30 s, 
54°C at 1 min, 72°C at 1 min 45 s. 
Construction of CD44-Rg Expression Vectors 
The CD44Rg expression vector was generated by subcloning the extracel- 
lular domain coding region from the CD44V10 NarI/KasI cassette cloning 
vector (22) into pCDM8 Ig FC (6). CD44HA-Rg was made by digesting 
CD44V10Rg with BglII and SphI (Gibco BRL, Gaithersburg, MD), puri- 
fying the plasmid on 1% agarose, the ends of the DNA fragment were blunt 
ended by Klenow (Boehringer Mannheim Corp.) in the presence of 2 mM 
dNTPs (Boehringer Mannheim Corp.), and then the plasmid was ligated 
with T4 ligase (GIBCO BRL). PCR was used to clone in the different CD44 
exons and domains from the ICAM-1 and CD34. The CD44 variable spliced 
exons were generated by PCR from CD44E-Rg and the oligonucleotide 
primers used were  as follows:  (a)  CD44V9,  V10-Rg insert was created 
with PCR primers CD44-E5-BglII, AGTGAAAGATCTAGCACTI'CA- 
GGAG,  and  CD44-E13-SphI,  ACATGCATGCATFGCITGATGTCA- 
GAGTAGAAG;  (b)  CD44V9-Rg  required  oligonucleotide  CD44-E13- 
SphI in conjunction with CD44-E13-BglI, GAAGATCTCAGAGTAAT- 
TCTCAGAGCITCT. The PCR template used to clone the Ig-domain from 
ICAM-1 was ICAM-1-Rg (10) and the PCR primers were ICAM-1-950-FP, 
GAAGATCTITTCCGGGGCCCAACGTG, and ICAM-l-1200-RP, ACA- 
TGCATGCTCGGGGGCCATACAGGAC. CD44/CD34-Rg insert was gen- 
erated from the template CD34-Rg (48) with oligonucleotides CD34-368-FP, 
GCCGCCAGATCTACTGCTACCCCAGAGTTACCT, and CD34-764-RP, 
GCCGCCGCATGCGTCACTFAGGATAGGAGAAGA. 
Hyaluronic Acid-binding Assay 
Transfectants were cultured in DME supplemented with 10% FBS and 1.5 
mg/ml G418  (GIBCO  BRL),  and/or 2  mM phenyl-et-GalNAc for  16  h. 
Cells were then washed, detached with PBS/0.5 mM EDTA, washed and 
radiolabeled with 100 mCi 5tCr (New Engand Nuclear, Boston, MA) for I h 
at 37°C. After several washes in DME, 104 radiolabeled cells were seeded 
per well onto 96-well plates previously coated with 5 mg/ml HA (Sigma), 
and allowed to attach for 30 min at 4°C. Nonadherent cells were removed 
by washing, adherent cells lysed with 1% SDS, and incorporated radioac- 
tivity determined in a 13 counter. 
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ELISA assay as previously described (44).  The protein concentration was 
determined  using the  BioRad  (Bradford)  protein  determination  assay 
(Richmond, CA), and then each fusion protein was run on an SDS-PAGE 
gel and silver stained to confirm the protein concentrations. To demon- 
strate  the  specificity of the  two  assays, CD44-Rg interaction  with  HA 
were  blocked by using an  anti-CD44 specific mAb MEM-85  (DeDiCa, 
Carlsbad, CA) and/or Bric235 (provided by Frances Spring). The ELISAs 
were  also done in the presence of isotype-matched control  mAbs pur- 
chased from Sigma. 
Glycosylation Determination 
To verify that the O-linked glycosylation inhibitor, phenyl-a-GalNAc, was 
generating deglycosylated fusion proteins the CD44-Rg proteins (100 ng) 
were analyzed by SDS-PAGE, transferred onto Nitrocellulose, and then 
detected  by  using MAA  (Maackia  amurensis Agglutinin) from a  DIG 
Glycan Differentiation Kit as recommended by the manufacturer (Boehr- 
inger Mannheim Corp.). 
Results 
Melanoma Transfectants  Expressing  CD44H 
Bind HA More Effectively Than the Same Cells 
Expressing  CD44E 
Previous reports suggested that CD44E, a  CD44 isoform 
containing variably spliced exons V8-V10, had a reduced 
lectin  function when compared with  CD44H,  the  CD44 
isoform containing no variably spliced exons. B  cell lym- 
phoma (Namalwa)  (51)  or T  cell leukemia  (Jurkat)  (38) 
cell transfectants expressing one  or the  other CD44 iso- 
forms were used to examine the ability of these two CD44 
isoforms to  bind  HA.  To examine  if this  difference in 
the HA-binding activity of membrane-bound CD44H and 
CD44E extended  to other cell types we prepared  mela- 
noma cell transfectants expressing either CD44H or CD44E. 
This  cell  line  was  chosen  since  it  does  not  express  any 
CD44 isoforms (Fig.  1 A). In addition, we elected to use 
stable  transfectants  rather  than  transient  transfectants 
since this would allow us to select CD44H and CD44E trans- 
fectants which express similar levels of CD44 and monitor 
the induction of endogenous CD44 transcripts, the expres- 
sion of which has been shown to be stimulated in some cell 
types by the agents used to facilitate transient transfection 
(50). Anti-CD44 mAb binding assays were used to identify 
melanoma  transfectants  expressing  approximately  equal 
levels of CD44H and CD44E (Fig.  1, B and C). To ensure 
that  the  transfection procedure did  not result  in  the  ex- 
pression of additional CD44 isoforms, we analyzed mRNA 
isolated from the melanoma transfectants and the parent 
cell line by reverse transcription-polymerase chain reaction 
(RT-PCR). As shown in Fig. 2 by RT-PCR with RNA iso- 
lated from stable transfected melanoma cells encoding ei- 
ther CD44H, CD44E or melanoma cells transfected with 
vector  only, express  the  expected  CD44  transcript.  The 
RT-PCR products run at the predicted size  on the ethid- 
ium  stained  gel  (Fig.  2 A),  a  random primed  32p-CD44 
probe did not detect any other mRNAs (Fig.  2 B), and a 
probe specific to exon V10 only detects the  CD44E iso- 
forms (Fig. 2 C). 
Binding  assays  with  the  melanoma  ceils  expressing 
CD44H and CD44E and the parent cell line showed that 
both transfectants were able to adhere to HA-coated plas- 
tic more effectively than  the  parent  cell line,  however, 
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Figure 1. Line drawings representing  flow cytometry profiles of 
stable transfected melanoma cells expressing different CD44 iso- 
forms.  (A-D)  The  cells were  stained  with either  an  isotype- 
matched control (shaded  profile) or a mAb to the "constant" region 
of CD44. (A) MC is the parent cell line which does not express 
CD44. (B) MC44H, (C) MC44E, (D) and MC44E-Trunc, express 
CD44H, CD44E, and  a CD44E deletion  mutant  missing exons 
El5 and El6, respectively. 
the CD44H transfectants bound more efficiently than the 
CD44E transfectants (Fig.  3 A). The binding of both the 
CD44H and CD44E transfectants to the HA-coated plastic 
could be reduced to background levels by the anti-CD44 
mAb indicating that the enhanced binding observed with 
the transfectants was due to the presence of CD44 (Fig. 3). 
These  results  are consistent with the  data obtained with 
the Namalwa and Jurkat transfectants and shows that the 
different binding capacities of CD44H and CD44E can oc- 
cur in both lymphoid and nonlymphoid cell types. 
Receptor Shedding Does Not Account for the 
Difference in the HA-binding Capacity of Melanoma 
Cell Transfectants  Expressing  CD44H or CD44E 
To examine the role that receptor shedding might play in 
the observed difference in HA binding between  CD44H 
and CD44E transfected melanoma cells, we prepared mel- 
anoma transfectants  expressing a  truncated  CD44E pro- 
tein, CD44E-trunc. CD44E-trunc is lacking exons E15 and 
El6 which compose the membrane proximal extracellular 
domain.  As  reported  by  Bartolazzi  et  al.  (4),  CD44E- 
trunc,  unlike  CD44E and  CD44H, is  not shed  from the 
transfected melanoma cells  after HA binding. Melanoma 
transfectants expressing similar levels of CD44E-trunc to 
those  of the  CD44H and  CD44E transfectants  were  se- 
lected for HA-binding studies  (Fig.  1).  RT-PCR analysis 
showed that the only CD44 transcripts expressed by these 
transfectants encoded CD44E-trunc (Fig.  2).  HA-binding 
studies with melanoma cells expressing CD44-trunc showed 
that these cells adhere to plastic more efficiently than cells 
transfected with CD44E, however, they did not adhere to 
the  HA-coated plastic  as  effectively as  transfectants  ex- 
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A 51Cr release assay was used to assess the binding to HA of sta- 
ble  MC  transfected  cells  with  CD44.  MC,  MC44H,  MC44E, 
MC44E-trunc were radiolabeled with 51Cr, and then seeded onto 
a plate with  5 mg/ml HA at 4°C for 30 min.  Nonadherent cells 
were washed  away, the  remaining cells  lysed,  and the released 
51Cr was determined. Each data point represents triplicate wells 
and standard deviations are indicated. The binding of the cells to 
HA was blocked by preincubating the cells  with an anti-CD44 
mAb (Bric235) at 10 Ixg/ml for 30 min at 4°C. 
Figure 2. RT-PCR of the CD44-transfected melanoma cells. RT- 
PCR DNA products were generated with primers that span the 
alternatively spliced exons E3-E17, and with one oligonucleotide 
within the variably spliced exon, E13, expressed in CD44E, and 
with primers to Actin. The RT-PCR products were run on a 2% 
agarose  gel  and  detected  by  (A)  ethidium  bromide,  and  then 
transferred  onto a Hybond Nylon membrane and probed with a 
(B) 32p-random primed probe to CD44E and (C) with a 32p-end- 
labeled  oligonucleotide  to  exon  V10  which  is  expressed  in 
CD44E but not CD44H. 
pressing  CD44H (Fig.  3).  As with  the other CD44 trans- 
fectants the adhesion of the CD44E-trunc transfectants to 
the HA-coated plastic could be prevented  by pretreating 
the cells with  a  blocking anti-CD44  mAb (Fig.  3).  These 
results suggest that the difference in the lectin capacity of 
the melanoma transfectants expressing CD44H or CD44E 
cannot  be  accounted  for  solely  on  the  basis  of  CD44E 
shedding after ligand-mediated receptor cross-linking, but 
suggest instead  a  direct  contribution  by the  alternatively 
spliced domain. 
Reduced HA Binding by CD44E Is Specifically 
Mediated by the Inclusion  of Variably Spliced Exons 
We have previously reported  the use of soluble immuno- 
globulin  fusion proteins,  containing  the  extracellular  do- 
main  of  CD44  (CD44-Rg),  to  study  CD44-HA  binding 
(44).  CD44H-Rg,  CD44E-Rg,  and  CD44-41R/A-Rg,  a 
CD44H point mutant that lacks HA-binding activity (44) 
were  used  for this  and  the  previous  study  (Fig.  4).  For 
this  study we  used  the  modified  chimeric gene  encoding 
CD44V10-Rg which includes  a  pair  of unique  restriction 
sites between the sequences encoding the "common" CD44 
exons and the human IgG (Fig. 4) (6, 22). These unique re- 
striction  sites  allow for the convenient subcloning of one 
or more DNA fragments encoding variably spliced CD44 
exons.  Subcloning  of  the  variably  spliced  exons  (V9, 
V8V9) into the cassette results in either loss of amino ac- 
ids from the common exon E5  and the loss of both com- 
mon exons E15 and E16.  To control for the loss of these 
sequences, a construct with both regions deleted was made 
and is referred to as CD44HA-Rg (Fig. 4). To examine the 
specificity and  the  role  of O-linked  carbohydrates  of the 
CD44 alternatively  spliced  exons in decreasing  the  lectin 
activity of CD44, the fourth Ig domain of ICAM-1 and the 
mucin domain of CD34 were inserted into the cassette. 
Comparison of the lectin activity of CD44H-Rg, CD44E- 
Rg,  and  CD44-41R/A-Rg  (44),  showed  that  CD44H-Rg 
bound HA in a concentration-dependent manner, whereas 
CD44E and CD44R/A-Rg have a greatly diminished HA- 
binding  activity  (Fig.  5  A).  Antibody  blocking  studies 
showed that the binding of the CD44HA-Rg to HA-coated 
plastic  could be  specifically inhibited  by a  blocking anti- 
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structs used to make soluble immunoglob- 
ulin fusion  proteins.  CD44H-Rg contains 
only the constant exons encoding  the ex- 
tracellular  domain,  and  CD44E-Rg  en- 
codes for the constant exons plus three al- 
ternatively spliced exons V8, V9, and V10. 
CD44V10-Rg was engineered to contain a 
BgllI and SphI site (6, 22) which were sub- 
sequently  used  to clone  individual  CD44 
variable exons,  ICAM-1, and  CD34  do- 
mains. 
CD44 mAb indicating that the lectin function of the CD44- 
Rgs is mediated by the CD44 moiety (Fig. 5 B). These ex- 
periments establish that HA-binding studies with CD44-Rgs 
can be used to study the effect of including variably spliced 
CD44 extracellular domains on CD44 lectin function. 
The  effect of including  variably spliced  exons V9  and 
V10, alone or the combination of V8 and V9, on CD44-HA 
binding was examined. Fig. 6 demonstrates that CD44HA- 
Rg has lectin-binding characteristics which are indistinguish- 
able from those of the CD44H-Rg, and its binding to HA 
can be inhibited by a blocking anti-CD44 mAb (Fig. 5 B). 
The  effect of including  the  variably spliced exons V9  or 
V10 individually on CD44 binding to HA was analyzed by 
testing the ability of the CD44V9-Rg and CD44V10-Rg fu- 
sion proteins to bind to plastic-immobilized HA. HA-bind- 
ing  studies  with  CD44V9-Rg  and  CD44V10-Rg  showed 
that inclusion of variably spliced exons V9 or V10 signifi- 
cantly reduces the ability of CD44HA-Rg to bind HA, with 
exon V10 having a more pronounced effect than exon V9 
(Fig. 6). Exon V10 has over twice the number of amino ac- 
ids as exon V9, and since inclusion of either V9 or V10 did 
not reduce HA binding to the levels seen with CD44E-Rg 
suggesting that the effect of the variably spliced exons on 
CD44-HA binding is additive. To investigate this possibil- 
ity we prepared a soluble CD44 fusion protein containing 
V8  and  V9  (CD44V8,  V9-Rg)  and  examined  its  lectin 
function.  As shown in Fig.  6,  CD44V8,V9-Rg  binding to 
HA was  intermediate  to  that  seen with  CD44HA-Rg or 
CD44E-Rg but lower than that seen with CD44V9-Rg in- 
dicating that the downregulation of CD44-HA-binding in- 
teraction by the inclusion of the variably spliced exons is 
additive. 
To determine if the ability of the variably spliced CD44 
extracellular domain exons to downregulate  CD44 lectin 
function is specific or simply a spacing effect, we prepared 
a  soluble  CD44  fusion protein in  which  the  cDNA frag- 
ment encoding the variably spliced CD44 exons present in 
CD44E-Rg were replaced with a  cDNA fragment encod- 
ing the fourth Ig-like domain of human ICAM-1 (Fig. 4). 
The fusion protein encoded by this chimeric gene, CD44/ 
ICAM-1-Rg, bound to HA (Fig. 7 A) and its binding to 
HA could be blocked with an anti-CD44 mAb (Fig. 7 B). 
As an additional control we analyzed the ability of ICAM- 
Rg, a fusion between the extracellular domain of ICAM-1 
and  human immunoglobulin to bind HA (Fig.  7 A).  Re- 
cently ICAM-1 has been purified from whole rat liver on 
an HA affinity column (39)  but the  extracellular domain 
has  not  been  analyzed  for  HA  binding.  We  found  that 
ICAM-1-Rg did not bind plastic-immobilized HA in this 
assay, and previously we have shown that ICAM-1-Rg can 
provide costimulatory signals to CD4 ÷ cells through inter- 
actions  with  LFA-1  (10).  These  results  suggest  that  the 
down modulation of HA binding observed with CD44E is 
specifically dictated  by the  variably spliced  CD44  exons 
and is not due to a spacing effect. 
O-linked Carbohydrate Chains on the Variably Spliced 
Exons of CD44E Inhibit the Lectin Function 
The  most  striking  feature  shared  by the  amino  acid  se- 
quence  of the variably spliced exons found in  CD44E is 
the  presence of multiple  Ser and Thr residues which  are 
potential sites of O-linked glycosylation, raising the possi- 
bility  that  O-linked  carbohydrates  may  interfere  with 
CD44-HA binding.  Initial attempts to address the role of 
O-linked carbohydrate modifications on CD44-HA bind- 
ing relied on the use of enzyme digestion to remove these 
moieties.  Although  these  experiments  seemed  to  indi- 
cate that O-linked carbohydrates play a role in regulating 
CD44-HA interactions, the results were variable (data not 
shown). We attributed this variability to incomplete diges- 
tion  and  designed  alternative methods to investigate the 
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Figure 5.  Binding  of CD44 fusion  proteins to immobilized  HA 
was assessed by ELISA. (A) Increasing amounts of CD44 fusion 
proteins were incubated on ELISA plates with 5 Fzg/ml  immobi- 
lized HA. Each data point represents the average and standard 
deviation  of triplicate  wells. (B) Specific blocking of 2 ixg/ml of 
CD44HA-Rg to 5 ~g/ml immobilized  HA in the presence of in- 
creasing amounts a anti-CD44  mAb but not an isotype-matched 
control IgG1. 
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Figure  6.  HA  binding of  CD44  fusion proteins with  variably 
spliced  exons.  CD44H and CD44HA-Rg  have very similar HA- 
binding profiles.  CD44E-Rg has a very low binding capacity to 
HA at the concentration tested. The CD44 fusion proteins with 
the variable spliced exons V9, V10, and V8 plus V9 have an inter- 
mediate HA-binding  capacity. 
role  of O-linked carbohydrate side  chains  on  CD44-HA 
interaction. Two approaches were used, first, we prepared 
CD44E-Rg in the presence of a specific inhibitor of O-linked 
glycosylation and examined its ability to bind HA. Second, 
we replaced the variably spliced exons in  CD44E  with a 
Ser and Thr rich sequence from the mucin CD34, which is 
decorated with  O-linked  carbohydrate moieties, and  ex- 
amined  the  ability  of  this  novel  fusion  protein  (CD44/ 
CD34-Rg) to bind to HA. 
CD44E-Rg and CD44H-Rg were produced in COS cells 
in the presence of phenyl-tx-GalNAc, a  compound which 
has been shown to block the addition of O-linked carbohy- 
drates to mucins without affecting cell growth, protein syn- 
thesis,  N-linked  glycosylation,  or  GAG  synthesis  ([29] 
and Wang, W.-C., personal communication). CD44H-Rg, 
CD44H-Rg O-glyc (-), CD44E-Rg, and CD44E-Rg O-glyc (-) 
made in the presence of phenyl-~x-GalNAc were analyzed 
by running 2 Ixg of the proteins on SDS-PAGE.  CD44H- 
Rg runs as a slightly lower molecular weight protein when 
made in the presence of phenyl-cx-galNAc demonstrating 
the loss of O-linked carbohydrates (Fig. 8 A). CD44E-Rg 
is extensively modified by N-linked carbohydrates, O-linked 
carbohydrates,  and  glycosaminoglycans  (8),  and  conse- 
quently runs as a diffuse band on SDS-PAGE when made 
in the presence or absence of phenyl-et-galNAc resulting 
in  no  strong detectable shift in  molecular weight  (Fig.  8 
A).  To ensure  a  reduction  in  O-linked  glycosylation oc- 
curred during the production of CD44E-Rg, a  lectin-blot 
was carried out.  100 ng of the proteins were separated on 
SDS-PAGE,  transferred to nitrocellulose,  and  then blot- 
ted with MAA, a lectin that detects (2-3)-linked sialic acids 
in  O-glycans  (data  not  shown).  The  lectin-blot  demon- 
strated that in the presence of the inhibitor that  CD44E- 
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Figure Z  The HA-binding capacity of CD44 is not reduced by 
exon spacing. (A) The Ig domain from ICAM-1 (CD44/ICAM-1- 
Rg) did not reduce the HA-binding capacity of CD44. ICAM-1- 
Rg fusion  protein does not bind to immobilized  HA. (B) The 
binding of the CD44/ICAM-1-Rg chimeric protein (2 t~g/ml) to 
HA was blocked in a concentration-dependent manner by an 
et-CD44 mAb but not by an isotype-matched control. 
Rg O-glyc (-) contains substantially less O-linked carbohy- 
drates.  Binding  studies  with  CD44E-Rg  produced  in  the 
presence  of  phenyl-et-GalNac  showed  that  this  protein 
bound  to plastic-immobilized HA as well as  CD44H-Rg 
(Fig.  8  B),  while  the  presence of O-linked  glycosylation 
did not influence the binding of CD44H-Rg to HA (Fig. 8 
C). The ability of the deglycosylated CD44E-Rg to bind to 
HA was inhibited by a blocking anti-CD44 mAb showing 
that  removal of the  O-linked sugars unmasked the  HA- 
binding  site  in  CD44E  (Fig.  8  D).  These  results  suggest 
that  O-linked  carbohydrates  play  an  important  role  in 
modulating the ability of CD44E to function as a lectin. 
To independently examine the role of O-linked carbo- 
hydrates in  the  regulation of CD44-HA binding we pre- 
pared CD44/CD34-Rg (Fig. 4). The chimeric gene encod- 
ing  this  protein  was  prepared  by  replacing  the  DNA 
sequence encoding the variably spliced exons in CD44E- 
Rg with a  DNA fragment encoding the mucin domain of 
CD34.  This region  of the  protein  contains  44%  Ser/Thr 
residues and is known to be decorated with a large number 
of O-linked carbohydrate moieties. As shown in Fig. 9, in- 
clusion of the CD34 mucin domain substantially reduced 
the ability of CD44H to bind to HA with the CD44/CD34- 
Rg fusion protein showing HA-binding properties which 
are comparable to those seen with CD44E-Rg. These re- 
suits provide independent evidence that the O-linked car- 
bohydrate moieties, which are added to the variably spliced 
exons found in CD44E, play a role in regulating the ability 
of this protein to function as a lectin. 
To test the role of the O-linked glycosylation in vivo, the 
stable  melanoma-transfected  cell  lines  were  grown  in  2 
mM phenyl-et-GalNAc, and then assayed for HA binding 
(Fig. 10).  A  dramatic increase in HA binding of the mela- 
noma  transfectants  expressing  CD44E  occurred  while  a 
slight increase in HA binding was observed with the CD44H 
transfectants. These data further support that alternatively 
splicing of CD44 provides a  mechanism of regulating the 
lectin function by the addition of mucin-like domains. 
Discussion 
Using melanoma cell transfectants expressing either CD44H 
or CD44E, we show that although both forms of CD44 are 
capable of binding HA, CD44H-Rg binds HA significantly 
better  than  CD44E-Rg.  This  difference  was  also  seen 
when the HA-binding activity of CD44H and CD44E, sol- 
uble immunoglobulin fusion proteins, was examined in a 
cell-free system using HA immobilized on plastic where 
CD44H binds HA at concentrations well below those re- 
quired  to  detect  CD44E  interacting  with  HA.  Experi- 
ments with CD44V9-Rg, CD44V10-Rg, CD44V8, V9-Rg, 
and CD44/ICAM-1-Rg showed that including the variably 
spliced exons found in CD44E, but not an ICAM-1 derived 
Ig domain, specifically inhibited CD44 lectin function.  In 
addition, the effect of each exon was additive, suggesting 
that the level of HA binding retained by a given CD44 iso- 
form can be finely regulated by varying the number of al- 
ternatively spliced exons present in that CD44 isoform. 
Inspection of the amino acid sequence of variably spliced 
CD44 domains found in CD44E showed that they are rich 
in Ser and Thr residues and thus likely to be highly modi- 
fied with O-linked carbohydrates in some cell types (Ser/ 
Thr content in exons V8-V10 varies from 43% for exon V9 
to 30% for exon V10). This led us to speculate that carbo- 
hydrate modifications of the variably spliced CD44 exons 
may play a  role in regulating the  HA-binding activity of 
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Figure 8. Production  of CD44E-Rg in the presence of an O-linked glycosylation inhibitor  generated a fusion protein with high capacity 
binding  to HA. (A) A comparison of the molecular weights by SDS-PAGE of CD44H-Rg and CD44E-Rg made in the presence of 
(O-Glyc (-)) and absence of phenyl-ct-galNAc. (B) Increasing concentrations  of CD44E-Rg produced in the presence of phenyl-ct-Gal- 
NAc bound to HA. (C) Increasing concentrations  of CD44H-Rg produced in the presence and absence of phenyl-a-GalNAc bound HA 
equivalently. (D) The binding to HA by CD44E-Rg (2 Ixg/ml)  was blocked by an ~x-CD44 mAb but not by an isotype-matched control. 
CD44.  Indeed,  such  mechanisms have been  observed to 
regulate the interaction between ICAM-1 and Mac-1 (11) 
and was proposed by Hodes and his colleagues to play a 
role in regulating CD44-HA binding (18). We investigated 
this possibility by digesting CD44E-Rg with a  number of 
glycosidases and examining its ability to bind HA. These 
experiments were variable but suggested a role for O-linked 
glycosylation in the modulation of the HA-binding activity 
of CD44E. We attributed these variable results to the in- 
ability of the enzymes to completely remove the carbohy- 
drates  from  the  native  protein.  We  circumvented  this 
problem by producing CD44E-Rg in the presence of an in- 
hibitor of O-linked carbohydrate addition. Binding studies 
with  CD44E-Rg  lacking  O-linked  carbohydrates  showed 
that it was able to bind HA as efficiently as CD44H-Rg. 
This was in  contrast  to  CD44H-Rg, where  the  O-linked 
carbohydrates had no effect on CD44-Rg/HA interaction. 
Furthermore, antibody blocking experiments demonstrated 
that the binding of the deglycosylated protein was specifi- 
cally mediated by the CD44 HA-binding site. If O-linked 
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Figure 9. A mucin domain from CD34 reduced the HA-binding 
capacity of CD44. A CD44/CD34-Rg chimeric protein bound only 
weakly to immobilized HA. 
carbohydrates play such an important role in modulating 
the lectin activity of CD44, we reasoned that it should be 
possible to mimic the effects of the variably spliced exons 
found  in  CD44E  by  including  carboxyl-terminal  to  the 
HA-binding domain of CD44, a polypeptide fragment from 
a mucin which is heavily substituted with O-linked carbo- 
hydrates. For this reason we prepared CD44/CD34-Rg,  a 
CD44 immunoglobulin fusion protein in which sequences 
corresponding to the variably spliced exons found in CD44E 
were replaced by a  Ser/Thr rich polypeptide fragment de- 
rived from CD34 (Ser/Thr content in this region is 44%). 
Binding studies with CD44/CD34-Rg showed that the in- 
clusion  of this  mucin fragment significantly inhibited  the 
ability  of CD44H  to  bind  HA.  Furthermore,  the  trans- 
fected  melanoma  cells  expressing  CD44E  and  CD44H 
bound equivalently HA when grown in the presence of 
2  mM  phenyl-tx-GalNAc in  a  CD44-dependent  manner. 
Taken together these results provide significant evidence 
that O-linked carbohydrate moieties added to the variably 
spliced exons of CD44 play a role in modulating the lectin 
activity of CD44. While O-linked glycosylation introduced 
by the variable spliced exons of CD44 modulate HA bind- 
ing, other factors may also be invoNed in regulating CD44 
isoform  function.  For  example,  two  recent  papers  have 
shown  that  N-linked  glycosylation reduces the  ability of 
CD44 to bind HA (26, 31). 
Although this study focused on the regulation of CD44- 
HA binding mediated by variably spliced exons V8-V10, 
inspection of the amino acid sequence of other extracellu- 
lar  domain  variably spliced  exons  (V2-V7)  showed  that 
they are also rich in Ser and Thr residues (Ser/Thr content 
varies from 18% for exon V5 to 32% for exon V2) suggest- 
ing that the glycosylation of these exons might also play a 
role in modulating the lectin activity of the CD44 common 
Figure 10. HA binding  of melanoma transfectants  grown in the 
presence of phenyl-a-GalNAc. A 5~Cr release assay was used to 
assess the binding to HA of the MC- transfected cells. Binding of 
MC44E cells to HA increased  to a level equivalent  to that of the 
MC44H cells when grown in the presence of an O-linked glycosy- 
lation inhibitor. All experiments were performed in sextuplicate. 
exons in CD44 isoforms which contain them. The function 
of two other lectins have been reported to be regulated by 
glycosylation. Removal of sialic acid from the asialoglyco- 
protein receptor results in the exposure of galactose moi- 
eties which bind to the receptor blocking the binding activ- 
ity of receptor preparations (3). Similarly, modification of 
CD22 with a 2,6-sialic acids blocks the ability of soluble re- 
ceptor preparations  to bind  to lymphocytes, presumably 
due to CD22-CD22  interactions involving sialic acid  (7). 
These results indicate that receptor glycosylation might be 
a common mechanism for regulating the function of a sub- 
set of lectins. The regulation of CD44-HA binding by gly- 
cosylation differs from that reported for the  asialoglyco- 
protein receptor and CD22 in two important ways. First, in 
CD44 there  are two levels at which glycosylation can be 
regulated;  one  is  at  the  level of alternative splicing,  the 
other  is  at  the  level  of expression  of the  glycosyltrans- 
ferases.  Second,  alternative  splicing  has  the  potential  to 
give rise to CD44 isoforms with graded HA-binding capac- 
ities. These two mechanisms allow for the tight regulation 
of the  HA-binding activity of CD44 isoforms containing 
variably spliced exons by glycosylation and suggest that a 
cell  can  rapidly  regulate  CD44/HA  interaction  by post- 
translational modification and/or alternative splicing. 
The molecular mechanism whereby carbohydrate modi- 
fication of the alternatively spliced CD44 exons modulates 
the  binding  activity of this  protein  remains to  be  deter- 
mined. It is possible that glycosylation might alter the con- 
formation of the molecule affecting its ability to function as 
a lectin. Alternatively, the negative charges on the O-linked 
carbohydrate chains  might perturb  and/or directly inter- 
fere with the  two clusters  of positively charged  residues 
which form the HA-binding site located at the NH2 termi- 
nus of all CD44 isoforms (55). 
Experiments designed to address the role of alternative 
splicing in the regulation of CD44-HA binding have been 
carried  out  and  yielded  mixed results.  CD44-negative  B 
cell lines transfected with human CD44H but not CD44E 
or CD44 isoforms with additional alternatively spliced ex- 
ons,  were  able  to  bind  to  hyaluronan-bearing cells  (51). 
Likewise, CD44-negative T  cells transfected with CD44H 
and CD44E showed different HA-binding activities after 
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by PMA and a number of anti-CD44 antibodies, whereas, 
CD44E  inducible HA binding was much more restricted. 
In addition, the CD44E transfectants induced HA binding 
at lower levels than that observed with the CD44H trans- 
fectants. Taken together these two reports suggest that al- 
though these  two  CD44  isoforms  can bind HA,  CD44H 
binds HA more effectively than CD44E. Furthermore, this 
work  supports the notion that there are multiple  mecha- 
nisms functioning to regulate HA binding by CD44. First, 
there appears to be an on/off switch that can regulate both 
isoforms, and second, the addition of alternatively spliced 
exons  along with regulation of the level  of glycosylation 
can result in the ability of fine tuning CD44/HA-binding 
interactions. These  observations contrast with the results 
by Dougherty et al.  (12) and in experiments showing that 
CD44-negative T cells transfected with murine CD44H or 
CD44E bound HA comparably (19). The results presented 
herein suggest that the reported differences  in the ability 
of a given CD44 isoform to bind to HA when expressed in 
different cell types may arise from differences in the ability 
of the cells to appropriately and/or sufficiently modify CD44 
isoforms  containing variably spliced  exons with O-linked 
carbohydrates. 
The ability of CD44H  to bind HA in a number of cell 
types is regulated. Cellular activation (14, 37), protein syn- 
thesis (42), and cytoplasmic domain phosphorylation (45) 
have been implicated  in the regulation of the interaction 
of CD44H  with HA.  The  finding that the  interaction of 
CD44E with HA is regulated by the addition of O-linked 
carbohydrate moieties  to the variably spliced exons adds 
an additional mechanism  to the regulation of CD44-HA 
binding and suggests  that in vivo the lectin activity of all 
CD44 isoforms is tightly regulated. Presently, it is not clear 
why  it  is  physiologically  important  to  regulate  the  HA- 
binding activity of this receptor,  however, its widespread 
distribution  and  unique role  in cell  activation,  adhesion, 
and migration suggests that its function as an HA-binding 
lectin requires precise regulation in vivo. 
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